drugset / Trial / NCT04235959

A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

NCT04235959

Phase 1 Completed 24 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to learn more about the safety and side effects of tirzepatide in Chinese participants with type 2 diabetes mellitus. The study will also measure how much tirzepatide gets into the bloodstream and how long it takes the body to remove it. The study will last about six or eight months for each participant.

Timeline

Start
2020-10-21
Primary completion
2021-08-17
Completion
2021-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 10 mg Subcutaneous
Subject Tirzepatide Peptide 15 mg Subcutaneous